Table 1.
Baseline characteristics of pT2N0M0 patients with ESCC.
| Characteristics | Total (n = 413) | Training cohort (n = 304) | Validation cohort (n = 109) |
|---|---|---|---|
| No. of patients (%) | No. of patients (%) | No. of patients (%) | |
| Age | |||
| < 65 | 208 (50.36) | 155 (50.99) | 53 (48.62) |
| ≥ 65 | 205 (49.64) | 149 (49.01) | 56 (51.38) |
| Gender | |||
| Female | 100 (24.21) | 68 (22.37) | 32 (29.36) |
| Male | 313 (75.79) | 236 (77.63) | 77 (70.64) |
| Location | |||
| Upper | 27 (6.54) | 23 (7.57) | 4 (3.67) |
| Middle | 273 (66.10) | 190 (62.50) | 83 (76.15) |
| Low | 113 (27.36) | 91 (29.93) | 22 (20.18) |
| Grade | |||
| Poor | 110 (26.63) | 85 (27.96) | 25 (22.94) |
| Well | 303 (73.37) | 219 (72.04) | 84 (77.06) |
| Length (cm) | |||
| > 2 | 342 (82.81) | 249 (81.91) | 93 (85.32) |
| ≤ 2 | 71 (17.19) | 55 (18.09) | 16 (14.86) |
| Lymph node harvested | |||
| > 10 | 152 (36.80) | 112 (36.84) | 40 (36.70) |
| ≤ 10 | 261 (63.20) | 192 (63.16) | 69 (63.30) |
| Radiotherapy | |||
| No | 354 (85.71) | 260 (85.53) | 94 (84.24) |
| Yes | 59 (14.29) | 44 (14.47) | 15 (13.76) |
| Chemotherapy | |||
| No | 308 (74.58) | 229 (75.32) | 79 (72.48) |
| Yes | 85 (20.58) | 75 (24.67) | 30 (27.52) |